Private Advisor Group’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Private Advisor Group’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,465	Closed	-$224K	–	2431
2024 Q1	$224K	Sell	3,465 -81	-2%	-$5.27K	﹤0.01%	2039
2023 Q4	$233K	Hold	3,546	–	–	﹤0.01%	1956
2023 Q3	$202K	Buy	3,546 +100	+3%	+$6.1K	﹤0.01%	1879
2023 Q2	$211K	Hold	3,446	–	–	﹤0.01%	1823
2023 Q1	$216K	Buy	+3,446	New	+$222K	﹤0.01%	1759
2020 Q3	–	Sell	-2,098	Closed	-$122K	–	2876
2020 Q2	$122K	Buy	+2,098	New	+$114K	﹤0.01%	1594
2014 Q4	–	Sell	-916	Closed	-$42K	–	1188
2014 Q3	$42K	Buy	+916	New	+$41.3K	﹤0.01%	1066

Other funds holding PBE

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CreativeOne Wealth Overland Park, Kansas $4.31B AUM 19.42% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

OCM

One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Private Advisor Group's PBE Position: Q2 2024 in Review

Private Advisor Group sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2024, closing a stake of 3,465 shares — an estimated $224K sold.

Private Advisor Group first reported a position in PBE in Q3 2014 and held it in 7 quarters. The position peaked at $233K in Q4 2023. 100 funds tracked by Wall St. Rank hold PBE as of Q2 2024.

Private Advisor Group reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2024 after selling out during the quarter.
Private Advisor Group sold 3,465 Invesco Biotechnology & Genome ETF shares in Q2 2024, an estimated $224K.
Private Advisor Group first reported a position in Invesco Biotechnology & Genome ETF in Q3 2014 and held it in 7 quarters.
Private Advisor Group's Invesco Biotechnology & Genome ETF position peaked at $233K in Q4 2023.
100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2024.

Based on Private Advisor Group's 13F filing for Q2 2024, filed 5 Aug 2024.